Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $41.99M
• Dividend Yield: N/A
• Average Volume (3M): 138.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 1.19%
• EPS Growth: 61.65%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -2.77
• Shares Outstanding: 8,639,904
• 10 Day Avg. Volume: 311,274
• 30 Day Avg. Volume: 138,826
• PEG Ratio: -0.03
• Price to Book (P/B): -0.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.30
• Enterprise Value/Market Cap: 2.13
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 0.65
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: $23.25
• Price Target Upside: 424.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 44 Neutral
• Price Target: $4.50 ▲(1.58%Upside)

Karyopharm Therapeutics' overall score is heavily impacted by significant financial challenges, including high leverage and negative equity. While there are promising clinical developments and strategic explorations, these are overshadowed by the company's ongoing financial instability and poor valuation metrics.

Positive Factors

Market Expansion

Reimbursement approvals were received in the UK, Italy, France, China, and South Korea in 2024.

Regulatory Approval

Xpovio previously received FDA Fast Track Designation for the treatment of patients with myelofibrosis.

Revenue Growth

Karyopharm reported 4Q24 Xpovio net product revenue of $29.3M, compared to $25.1M for 4Q23.

Negative Factors

Competition

Challenges of rising competition and higher gross-to-net adjustments were noted as headwinds to sales.

Financial Performance

KPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter.

Workforce Reduction

Karyopharm announced that it would be reducing its workforce by roughly 20% after confidential discussions with potential investors regarding potential financing transactions failed to yield any results.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel drugs for the treatment of cancer and other major diseases. Headquartered in Newton, Massachusetts, the company is primarily engaged in developing therapies that target nuclear transport and related pathways. Their lead compound, selinexor, is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound that has been approved for the treatment of multiple myeloma and diffuse large B-cell lymphoma.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the sale of its pharmaceutical products, particularly selinexor, which is marketed under the brand name XPOVIO. The company earns revenue from product sales in the United States and collaborates with international partners for distribution outside the U.S. Additionally, Karyopharm engages in licensing agreements and strategic partnerships with other pharmaceutical companies to expand its market reach and support drug development, which can include upfront payments, milestone payments, and royalties on sales. The company also invests in research and development to expand its pipeline of investigational drugs, aiming to bring additional products to market and diversify its revenue streams.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges with declining revenue, persistent net losses, high leverage, and negative equity. Cash flow is negative, necessitating reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	108.71M	191.44M	277.97M	228.62M	273.45M
Total Debt	194.52M	177.02M	172.98M	169.29M	117.93M
Total Liabilities	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 4.43 is above the 20-day moving average (MA) of 4.40, below the 50-day MA of 4.50, and below the 200-day MA of 8.14, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.02 is Neutral, neither overbought nor oversold. The STOCH value of 52.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	S$1.63B	4.24	2.87%	2.60%	17.84%	20.03%
CNTB	49 Neutral	$125.65M	―	-58.89%	―	―	―
HOWL	45 Neutral	$62.37M	―	-82.81%	―	-92.95%	-50.02%
KPTI	44 Neutral	$41.99M	―	41.08%	―	1.19%	61.65%
XFOR	44 Neutral	$8.68M	0.67	121.75%	―	―	―
PEPG	40 Underperform	$47.77M	―	-75.45%	―	―	14.06%

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Explores Financing and Strategic Options

Karyopharm Therapeutics has been in discussions with potential investors to explore financing options to extend its cash runway, but no transaction has been finalized. The company is evaluating strategic alternatives, including potential mergers or sales, to maximize shareholder value. Additionally, Karyopharm is reducing its workforce by 20% to manage operating expenses, while continuing to focus on its commercial and clinical efforts in multiple myeloma and myelofibrosis. The company reported a net product revenue of $21.1 million in the first quarter of 2025, with a total revenue of $30 million, despite being impacted by increased returns of expired products.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment

At the 2025 Annual Meeting of Stockholders held on May 28, Karyopharm Therapeutics Inc. announced that its stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available by 450,000. Additionally, Garen G. Bohlin and Zhen Su were elected as Class III directors for a three-year term. The stockholders also approved the compensation of the company’s named executive officers and recommended annual advisory votes on this compensation. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.